Cargando…

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

PURPOSE: Sunitinib is a first-line advanced renal cell carcinoma (RCC) standard of care. In a randomized phase II trial comparing sunitinib treatment schedules, separate exploratory biomarker analyses investigated the correlations of efficacy with selected serum, germ line single-nucleotide polymorp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Motzer, Robert J., Hutson, Thomas E., Hudes, Gary R., Figlin, Robert A., Martini, Jean-Francois, English, Patricia A., Huang, Xin, Valota, Olga, Williams, J. Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175044/ https://www.ncbi.nlm.nih.gov/pubmed/25100134 http://dx.doi.org/10.1007/s00280-014-2539-0

Ejemplares similares

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
por: Harmon, Charles S., et al.
Publicado: (2013)

A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma
por: English, Patricia A, et al.
Publicado: (2016)

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α
por: Patil, S, et al.
Publicado: (2012)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
por: Rini, Brian I., et al.
Publicado: (2011)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J J, et al.
Publicado: (2018)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J. J., et al.
Publicado: (2017)

Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma
por: Cella, David, et al.
Publicado: (2014)

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
por: Molina, Ana M., et al.
Publicado: (2010)

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
por: Beuselinck, B, et al.
Publicado: (2013)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Common germ-line polymorphism of C1QA and breast cancer survival
por: Azzato, E M, et al.
Publicado: (2010)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
por: Motzer, R J, et al.
Publicado: (2013)

Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial
por: Motzer, Robert J., et al.
Publicado: (2022)

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
por: DePrimo, Samuel E, et al.
Publicado: (2007)

Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials
por: Ganapathi, Ram N, et al.
Publicado: (2011)

Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
por: Voss, Martin H, et al.
Publicado: (2016)

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
por: Khosravan, Reza, et al.
Publicado: (2016)

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
por: Blagoev, Krastan B., et al.
Publicado: (2013)

Influence of VEGFR single nucleotide polymorphisms on the efficacy of sunitinib therapy against renal cell carcinoma
por: Liu, Rui, et al.
Publicado: (2017)

Epigenetic reprogramming in the porcine germ line
por: Hyldig, Sara MW, et al.
Publicado: (2011)

Epigenetic reprogramming in the porcine germ line
por: Hyldig, Sara MW, et al.
Publicado: (2011)

Genetic Mosaics and the Germ Line Lineage
por: Samuels, Mark E., et al.
Publicado: (2015)

Genetic diversity among INERA maize inbred lines with single nucleotide polymorphism (SNP) markers and their relationship with CIMMYT, IITA, and temperate lines
por: Dao, Abdalla, et al.
Publicado: (2014)

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
por: Cebrián, Arancha, et al.
Publicado: (2017)

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
por: Scartozzi, M, et al.
Publicado: (2013)

Phase II study of sunitinib as second-line treatment for advanced gastric cancer
por: Bang, Yung-Jue, et al.
Publicado: (2010)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example
por: Burotto, Mauricio, et al.
Publicado: (2014)

Impact of gut microbiota on the fly's germ line
por: Elgart, Michael, et al.
Publicado: (2016)

Human germ line editing—roles and responsibilities
por: Lunshof, Jeantine E.
Publicado: (2015)

The remodeling of Z-DNA in the mammalian germ line
por: Meng, Yingying, et al.
Publicado: (2022)

Sources of discordance among germ-line variant classifications in ClinVar
por: Yang, Shan, et al.
Publicado: (2017)

Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate
por: Gasent Blesa, Joan Manel, et al.
Publicado: (2009)

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
por: Géczi, Lajos, et al.
Publicado: (2020)

Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma
por: Diekstra, Meta H. M., et al.
Publicado: (2015)

Identification of genes expressed in the hermaphrodite germ line of C. elegans using SAGE
por: Wang, Xin, et al.
Publicado: (2009)

Environmentally Induced Transgenerational Epigenetic Reprogramming of Primordial Germ Cells and the Subsequent Germ Line
por: Skinner, Michael K., et al.
Publicado: (2013)

Nucleotide Polymorphisms and Haplotype Diversity of RTCS Gene in China Elite Maize Inbred Lines
por: Zhang, Enying, et al.
Publicado: (2013)

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
por: Choueiri, T. K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cbtpdc067jjhqqlsj96le40crj